Varithena Microfoam Treatment

This page starts with the foam, because that is the part a reader can ask about. PubMed Central hosts a study that describes polidocanol endovenous microfoam, approved in the USA as Varithena, as made with a very low concentration of nitrogen plus carbon dioxide and oxygen.

The hub follows Varithena through two questions a patient asks before agreeing to it: what the foam has been reported to do, and who should not receive it.

Two pages, in the order you need them

Read them before the visit, not during it.

• Varithena Results for Visible Varicose Veins: what is reported for veins you can see.
• Who Should Not Receive Polidocanol Foam: the people for whom the foam is a question to settle first.

What the study reports

The same PubMed Central study concludes that Varithena provided significantly greater symptom relief and improvement in leg appearance compared with placebo. It also calls the foam an important addition to the treatment options for varicose veins. That is one study's account of one product, so ask your clinician how the findings apply to your legs, and do not read them as a promise.

Further reading on the foam

The full text of the PubMed Central multicenter study of Varithena is open to read. For the wider treatment family, the Cleveland Clinic page on sclerotherapy for spider veins sits next to it. Two recovery reads cover the days after treatment: Kaiser Permanente on what to expect at home after sclerotherapy and the Vein Directory recovery guide.

If the sign that sent you here has not eased, or keeps coming back, book a visit and ask which treatment fits your veins.